Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

United States Dry Eye Syndrome Drug Forecast and Market Analysis to 2024 - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024" report to their offering.

Drug sales in the US reached $1.3 billion during 2014, making it the largest market within the 9MM. After an initial period of minimal growth, we estimate that the DES market will undergo a period of steady growth from 2016 and beyond, but this growth will begin to wane slightly towards the end of the forecast period.

This growth is mainly attributed to the expected introduction of the highly anticipated pipeline DES drug Lifitegrast in late 2016, and additional pipeline products in 2018. This expansion of treatment options for DES patients will have the added effect of increasing overall treatment rates in the US.


  • Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US, including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US DES market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles

5.2.1 Restasis (cyclosporine)

5.2.2 Diquas (diquafosol tetrasodium)

5.2.3 Mucosta ophthalmic solution (rebamipide)

5.2.4 Ikervis (cyclosporine)

5.2.5 Artificial Tears

5.2.6 Other Therapies

6 Unmet Need and Opportunity

6.1 Overview

6.2 New Therapies for DES

6.3 Better Diagnostic Tools

6.4 Appropriate Clinical Trial Design to Secure Regulatory Approval

6.5 Simplified Dosing

6.6 Patient Education to Improve Tolerance and Compliance

6.7 Improved Physician and Patient Disease Awareness

7 Pipeline Assessment

7.1 Overview

7.2 Clinical Trial Mapping

7.2.1 Clinical Trial Design for DES

7.2.2 Ora for DES Drug Development

7.3 Promising Drugs in Clinical Development

7.3.1 Lifitegrast

7.3.2 Tavilermide

7.3.3 Visomitin

7.3.4 RGN-259

7.3.5 Cis-UCA

7.3.6 SI-614

7.4 Promising Drugs in Early-Stage Development

7.4.1 KPI-121

7.4.2 Ozagrel

7.4.3 P-321

7.4.4 Dextenza (OTX-DP)

7.5 Other Drugs in Development

8 Market Outlook

9 Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.